Controversies in the medical management of persistent and recurrent acute otitis media: Recommendations of a clinical advisory committee

Annals of Otology, Rhinology and Laryngology

Volumn 109, Issue 8 II SUPPL. 183, 2000, Pages 2-12

  Pichichero, M E ^a   Reiner, S A ^a   Brook, I ^a   Gooch III, W M ^a   Yamauchi, T ^a   Jenkins, S G ^a   Sher, L ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Cephalosporin; Drug resistant Streptococcus pneumoniae; Haemophilus influenzae; Moraxella catarrhalis; Otitis media; Penicillin

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFACLOR; CEFDINIR; CEFIXIME; CEFPODOXIME PROXETIL; CEFPROZIL; CEFTIBUTEN; CEFTRIAXONE; CEFUROXIME AXETIL; CEPHALOSPORIN; CLARITHROMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; LORACARBEF; PENICILLIN G; SULFAFURAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; CHILD; CHILDHOOD DISEASE; DRUG MISUSE; HAEMOPHILUS INFLUENZAE; HUMAN; INFANT; MORAXELLA CATARRHALIS; OTITIS MEDIA; PERSISTENT INFECTION; PRIORITY JOURNAL; RECURRENT INFECTION; REVIEW; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

EID: 0033871525     PISSN: 00034894     EISSN: None     Source Type: Journal    
DOI: 10.1177/00034894001090s801     Document Type: Review

References (84)

1. Acute otitis media: Management and surveillance in an era of pneumococcal resistance. A report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group
2. Antimicrobial therapy of acute otitis media: Review of treatment recommendations
3. Treatment of acute otitis media in an era of increasing microbial resistance
4. Review of consensus reports on management of acute otitis media
5. Strategies for dealing with amoxicillin failure in acute otitis media
6. Persistent acute otitis media: I. Causative pathogens
7. Cefprozil treatment of persistent and recurrent acute otitis media
8. Epidemiology of otitis media during the first seven years of life in children in Greater Boston
9. Epidemiology of otitis media onset by six months of age
10. Increasing prevalence of recurrent otitis media among children in the United States
11. The heritability of otitis media. A twin and triplet study
12. A meta-analytic review of the risk factors for acute otitis media
13. Causative pathogens, antibiotic resistance and therapeutic considerations in acute otitis media
14. Prevalence of various respiratory viruses in the middle ear during acute otitis media
15. Centers for Disease Control and Prevention. Defining the public health impact of drug-resistant Streptococcus pneumoniae: Report of a working group
16. Prevalence of antimicrobial-resistant pathogens in middle ear fluid: Multinational study of 917 children with acute otitis media
17. Penicillin-resistant Streptococcus pneumoniae in acute otitis media: Risk factors, susceptibility patterns and antimicrobial management
18. Bacterial interference in the adenoids of otitis media-prone children
19. Therapy of acute otitis media. Clinical and economic aspects
20. Otitis media and child development: Should we worry?
21. Office visits for otitis media: United States, 1975-1990
22. Clinical efficacy of antimicrobial drugs for acute otitis media: Metaanalysis of 5400 children from thirty-three randomized trials
23. Pharmacokinetics and pharmacodynamics of new and old antimicrobial agents for acute otitis media
24. Bacteriology and beta-lactamase activity in ear aspirates of acute otitis media that failed amoxicillin therapy
25. Bacterial interference in the nasopharynx following antimicrobial therapy of acute otitis media
26. Respiratory viruses interfere with bacteriologic response to antibiotic in children with acute otitis media
27. Do children with recurrent Haemophilus influenzae otitis media become infected with a new organism or reacquire the original strain?
28. Compliance of pediatric patients with treatment involving antibiotic suspensions: A pilot study
29. Pharmacoeconomic impact of factors affecting compliance with antibiotic regimens in the treatment of acute otitis media
30. Acute otitis media: I. Improving diagnostic accuracy
31. Acute otitis media: Making an accurate diagnosis
32. Audiometry and tympanometry in relation to middle ear effusions in children
33. Morbidity and mortality in children associated with the use of tobacco products by other people
34. Tympanometry and otoscopy prior to myringotomy: Issues in diagnosis of otitis media
35. Microbiology of recently treated acute otitis media compared with previously untreated acute otitis media
36. Otoscopy for the diagnosis of otitis media
37. The spread of multiply resistant Streptococcus pneumoniae at a day care center in Ohio
38. Detection of middle ear effusion by acoustic reflectometry
39. Diagnosis and antibiotic treatment of acute otitis media: Report from the International Primary Care Network
40. Antimicrobial use for pediatric upper respiratory infections: Reported practice, actual practice, and parent beliefs
41. Treatment of early recurrences of acute purulent otitis media; value of myringotomy
42. Changing the treatment paradigm for acute otitis media in children
43. Conjunctivitis-otitis syndrome
44. Bacterial etiology of conjunctivitis-otitis media syndrome
45. Relation of the outcome of conjunctivitis and the conjunctivitis-otitis syndrome to identifiable risk factors and oral antimicrobial therapy
46. Implications of drug-resistant Streptococcus pneumoniae for otitis media
47. Multiply resistant pneumococcus causing meningitis: Its epidemiology within a day-care centre
48. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
49. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media
50. Comparison of ceftriaxone and trimethoprim-sulfamethoxazole for acute otitis media
51. Amoxicillin middle ear fluid penetration and pharmacokinetics in children with acute otitis media
52. Single-dose ceftriaxone versus 10 days of cefaclor for otitis media
53. One dose ceftriaxone vs. ten days of amoxicillin/clavulanate therapy for acute otitis media: Clinical efficacy and change in nasopharyngeal flora
54. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae
55. Eradication by ceftriaxone of Streptococcus pneumoniae isolates with increased resistance to penicillin in cases of acute otitis media
56. Cefaclor v amoxicillin in treatment of acute otitis media
57. Single-dose intramuscular ceftriaxone for acute otitis media in children
58. Penetration of ceftriaxone into the middle ear fluid of children
59. Equivalent efficacy and reduced occurrence of diarrhea from a new formulation of amoxicillin/clavulanate potassium (Augmentin) for treatment of acute otitis media
60. Bacteriologic and clinical efficacy of cefixime compared with amoxicillin in acute otitis media
61. Cefixime compared with amoxicillin for treatment of acute otitis media
62. Bacteriologic efficacy of a three-day intramuscular ceftriaxone regimen in non-responsive acute otitis media
63. Rationale behind high-dose amoxicillin therapy for acute otitis media due to penicillin-nonsusceptible pneumococci: Support from in vitro pharmacodynamic studies
64. Comparative activity of ampicillin, amoxycillin, amoxycillin/clavulanate and cefotaxime against 189 penicillin-susceptible and -resistant pneumococci
65. Assessing the treatment alternatives for acute otitis media
66. Amoxicillin twice daily in the treatment of acute otitis media in infants and children
67. Single dose amoxicillin treatment of acute otitis media
68. Middle ear fluid concentrations of amoxicillin after large dosages in children with acute otitis media
69. Interpretation of middle ear fluid concentrations of antibiotics: Comparison between ceftibuten, cefixime and azithromycin
70. Differential absorption of amoxicillin from the human small and large intestine
71. Dose-dependent absorption of amoxycillin and bacampicillin
72. Bioavailability of ampicillin and amoxicillin in fasted and nonfasted subjects
73. Nonlinearity of amoxicillin absorption kinetics in human
74. Reappraisal of amoxycillin absorption kinetics
75. Safety and tolerability of a new formulation (90 mg/kg/day divided every 12 h) of amoxicillin/clavulanate (Augmentin®) in the empiric treatment of pediatric acute otitis media caused by drug-resistant Streptococcus pneumoniae
76. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants
77. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers
78. Efficacy of heptavalent conjugate pneumococcal vaccine (Wyeth Lederle) in 37,000 infants and children: Impact on pneumonia, otitis media, and an update on invasive disease
79. Shortened course of antibiotic therapy for acute otitis media, sinusitis, and tonsillopharyngitis
80. Treatment of acute otitis media with a shortened course of antibiotics: A meta-analysis
81. Five-day versus ten-day treatment of acute otitis media with cefprozil